Coronary heart disease (CHD) is the leading cause of mortality in the industrialized world and that might also soon be the case in other parts of the world. There are several easily measured and potentially modifiable risk factors that account for a substantial proportion of the risk of CHD. The effect of risk factors interventions appears to be consistent in both genders, across different geographic regions, and by all ethnic groups, suggesting that approaches to prevention can be based on similar principles worldwide. Optimal target levels for serum cholesterol and blood pressure are not yet clear. Future risk CHD reduction will mainly be achieved by improved primary prevention.
DaviglusMLStamlerJPirzadaA. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA. 2004;292(13):1588–1592.
2.
YusufSHawkenSOunpuuSINTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952.
3.
BartecchiCMacKenzieTDSchrierRW. The human costs of tobacco use (1). N Engl J Med. 1994;330(13):907–912.
4.
MacKenzieTBartecchiCESchrierRW. The human costs of tobacco use (2). N Engl J Med. 1994;330(14):975–980.
5.
US Department of Health and Human Services. The Health Benefits of Smoking Cessation. Washington, DC: US Department of Health and Human Services; 1990.
6.
LamTHeY. Passive smoking and coronary heart disease: a brief review. Clin Exp Pharmacol Physiol. 1997;24(12):993–996.
7.
McEwenAHajekPMcRobbicHWestR. In:Manual of Smoking Cessation. Oxford:Blackwell Publishers; 2006
8.
MansonJTostesonHRidkerPM. The primary prevention of myocardial infarction. N Engl J Med. 1992;326(21):1406–1416.
9.
BarthJBengelJSmoking cessation in patients with coronary heart disease: risk reduction and an evaluation of the efficacy of interventions. In:JordanJBardeBZeiherAM (Eds.),Contributions Toward Evidence-based Psychocardiology—A Systematic Review of the Literature. Washington, DC:American Psychological Association; 2007:83–105.
10.
The Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update: a U.S. Public Health Service report. Am J Prev Med. 2008;35(2):158–176.
11.
BlackJH 3rd. Evidence base and strategies for successful smoking cessation. J Vasc Surg. 2010;51(6):1529–1537.
12.
MeyersDGNeubergerJSHeJ. Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;54(14):1249–1255.
13.
StampferMJHuFBMansonJERimmEBWillettWC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343(1):16–22.
14.
de LorgerilMSalenPMartinJLMonjaudIDelayeJMamelleN. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779–785.
15.
.Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354(9177):447–455.
16.
Kris-EthertonPMHarrisWSAppelLJAmerican Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747–2757.
17.
GeleijnseJMGiltayEJSchoutenEGAlpha Omega Trial Group. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J. 2010;159(4):539–546.
18.
Dietary Guidelines for Americans. US Dept of Health and Human Services and US Dept of Agriculture. 6th ed.Washington, DC:US Government Printing Office; 2005.
19.
MichaRWallaceSKMozaffarianD. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation. 2010;121(21):2271–2283.
20.
GuiraudVAmorMBMasJLTouzéE. Triggers of ischemic stroke: a systematic review. Stroke. 2010;41(11):2669–2677.
21.
RehmJTaylorBMohapatraS. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010;29(4):437–445.
22.
PaffenbargerRSJrHydeRTWingALHsiehCC. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med. 1986;314(10):605–613.
23.
OldridgeNBGuyattGHFischerMERimmAA. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA. 1988;260(7):945–950.
24.
GrahamIAtarDBorch-JohnsenK. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(suppl 2):S1–S113.
25.
WhitlockGLewingtonSSherlikerPProspective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–1096.
26.
World Health Organization: Obesity. Preventing and Managing the Global Epidemic: Report of a WHO Consultation. Geneva:World Health Organization; 2000.
27.
DespresJMoorjaniSLupienPJTremblayANadeauABouchardC. Regional distribution of body fat, plasma lipoprotein, and cardiovascular disease. Arteriosclerosis. 1990;10(4):497–511.
28.
National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res. 1998;6(suppl 2):51S–209S.
29.
RejeskiWBrawleyLRAmbrosiusWT. Older adults with chronic disease: benefits of group-mediated counseling in the promotion of physically active lifestyles. Health Physiol. 2003;22(4):414–423.
30.
AlbertiKGEckelRHGrundySM. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
31.
DiMatteoMRLepperHSCroghanTW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–2107.
32.
BlumenthalJSherwoodABabyakMA. Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA. 2005;293(13):1626–1634.
33.
ThombsBDde JongePCoyneJC. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA. 2008;300(18):2161–2171.
34.
WhooleyMAde JongePVittinghoffE. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA. 2008;300(20):2379–2388.
35.
ChidaYSteptoeA. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol. 2009;53(11):936–946.
36.
LindenWStosselCMauriceJ. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med. 1996;156(7):745–752.
37.
DusseldorpEvan ElderenTMaesSMeulmanJKraaijV. A meta-analysis of psychoeduational programs for coronary heart disease patients. Health Psychol. 1999;18(5):506–519.
38.
ManciaGDe BackerGDominiczakA. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–1536.
39.
JATOS Study Group. Principal results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res. 2008;31(12):2115–2127.
40.
CushmanWCEvansGWByingtonRPACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585.
41.
MesserliFHManciaGContiCR. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med. 2006;144(12):884–893.
42.
SleightPRedonJVerdecchiaPetal;. on behalf of the ONTARGET Investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial Study. J Hypertens. 2009;27(7):1360–1369.
43.
FarnettLMuldrowCDLinnWDLuceyCRTuleyMR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?. JAMA. 1991;265(4):489–495.
44.
FagerbergBWikstrandJBerglundGSamuelssonOAgewallS. Mortality rates in treated hypertensive men with additional risk factors are high but can be reduced: a randomized intervention study. Am J Hypertens. 1998;11(1 Pt 1):14–22.
45.
VerschurenWMMJacobsDRBloembergBPM. Serum total cholesterol and long term coronary heart disease mortality in different cultures: twenty five year follow up of the Seven Country Study. JAMA. 1995;274(2):131–136.
46.
American Heart Association, National Heart, Lung, and Blood Institute. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation. 1990;81(5):1721–1733.
47.
BaigentCKeechAKearneyPMCholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
48.
RidkerPMRifaiNCookNRBradwinGBuringJE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326–333.
49.
DenkeMA. Dietary fats, fatty acids, and their effects on lipoproteins. Curr Atheroscler Rep. 2006;8(6):466–471.
50.
ShepherdJCobbeSMFordI. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–1307.
51.
DownsJRClearfieldMWeisS. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of FCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–1622.
52.
RydénLStandlEBartnikMetal. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.
53.
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
54.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.
55.
MattilaTKde BoerA. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs. 2010;70(17):2229–2245.
56.
DhawanSSQuyyumiAA. Rheumatoid arthritis and cardiovascular disease. Curr Astheroscler Rep. 2008;10(2):128–133.
57.
HanssonGK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
58.
RidkerPMDanielsonEFonsecaFAetal. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
